Introduction
In contrast to the success of immunomodulatory disease-modifying therapies (DMTs) in the treatment of relapsing-remitting multiple sclerosis (RRMS), most clinical trials have failed to demonstrate efficacy for these DMTs in slowing disease progression in primary progressive multiple sclerosis (PPMS) or secondary progressive multiple sclerosis (SPMS). 1, 2 Part of this discrepancy stems from the increased understanding of the etiology and standardized methods to measure relapses, which have remained largely elusive for progression. Consequently, the repurposing of RRMS DMTs and trial design methods toward progressive multiple sclerosis (PMS) may produce misleading results. Indeed, the same or highly similar DMTs have demonstrated different results in different PMS trials. 2 Since the progressive patient population is heterogeneous in terms of level of inflammatory activity, disease duration, and disability, patient inclusion criteria can also potentially influence trial outcomes. 3 This variability then makes it difficult to determine whether the reported efficacy in positive trials is due to trial design or actual targeting of the drivers of PMS. In response to these challenges, there has been increased focus on the development and validation of biological correlates of progression in multiple sclerosis (MS), and Phase 2 trials for prospective DMTs are shifting toward outcome measures of neurodegeneration. 1, 2 We discuss the factors contributing to trial variability, how these factors may have influenced conflicting trial outcomes, and some of the efforts toward facilitating better outcomes. transition phase from RRMS to SPMS. In the completed studies, the active PMS patients were the most responsive to the immunomodulatory DMTs, 5 thus studies with a higher proportion of these patients were more likely to be positive (Table 1) . This suggests that immunomodulatory therapies can be efficacious in early stages of the disease, but beyond a certain age or threshold of disability accumulation, different types of therapies may be required. To identify these therapies, future trials will need to better stratify cohorts by levels of inflammation, disability, gender, and age.
Aging itself may be a critical driver of progression, 14, 15 particularly the aging of the immune system. The onset of PPMS is usually later than RRMS, such that after age 50 individuals are more likely to be diagnosed with PPMS. 16 Since SPMS occurs after a period of RRMS that can last 20 years or longer, the transition to SPMS is most common as patients reach their mid-50s. 17 This corresponds to the time when the body starts showing signs of immunosenescence and demonstrates less robust adaptive inflammatory responses, 18 consistent with "inactive" forms of PMS. Although the incidence of MS is higher in women, the gender disparity is greater for RRMS than PPMS, and progression is often more aggressive in men. 19, 20 This may be attributable to the slower rate of immunological decline in women, which has also been suggested to contribute to longevity. 21 However, aging involves a constellation of systematic changes, including decreased myelination and repair capacity in the central nervous system (CNS), all of which may influence progression. 14 The age-related accumulation of CNS iron is of particular note, since iron is a feature of MS lesion formation, 22 and the oxidation of Fe 2+ to Fe 3+ is a potent inducer of neurodegenerative oxidative stress. 23 Consequently, the screening of patients for signs of immunosenescence or iron dysregulation could facilitate the testing of more sub-population targeted DMTs.
Drivers of disease progression
The inflammatory drivers of relapses are relatively well understood, which has led to the development of several DMTs highly effective at preventing relapses. 24 In contrast to relapses, progression is generally characterized by diffuse neurodegeneration not obviously associated with specific inflammatory activity, and the underlying mechanisms are less clear. 25 Demyelination itself can cause axons to lose trophic support, and thus induce neurodegeneration, 26 but the lack of translation by highly effective RRMS DMTs suggests that the axonal pathology in PMS may be driven by distinct mechanisms from relapses. Cortical pathology appears to play a prominent role 27 and is associated with the presence of meningeal inflammation and ectopic lymphoid follicles. 28, 29 While RRMS has been described as a T cell-driven disease, these observations suggest an enhanced role for B cells in progression. 30 This may explain the recent success of the B cell-depleting therapy, ocrelizumab, in a trial for PPMS; 10 however, it remains unclear how well it actually targets the CNS-resident B cell follicles. Progression may also involve a shift from the adaptive to the innate immune system, as microglial activation is associated with diffuse neuropathology in PMS. 31 Non-inflammatory-mediated mechanisms of axonal pathology are also possible, as synaptic alterations, mitochondrial dysfunction, and defects in axon transport have been reported in PMS. 32 Irrespective of the cause, treatments for advanced PMS are likely to require neuroprotective activity.
Measures of disease progression
Unlike annualized relapse rate, which is an easily quantifiable efficacy metric for RRMS, the assessment of disability progression is more subjective and time intensive. A change in the Expanded Disability Status Scale (EDSS) score is the accepted standard primary outcome measure in Phase 3 progressive trials. 33 However, disability is multifaceted including both physical and cognitive impairment, while EDSS is heavily weighted on physical disability and becomes increasingly insensitive to small changes in progression as disability increases. 34 Therefore, newer trials are also incorporating the more quantifiable features of the Multiple Sclerosis Functional Composite (MSFC), 33 such as the timed 25′ walk test (T25FW) and 9-hole peg test (9-HPT), as well as the symbol digit modality test, which has been demonstrated to be a highly sensitive and easily performed test of cognitive function in MS patients 35 (Table 2 ). Since these measures are not yet accepted or standardized by regulatory agencies, it can be difficult to prioritize or reconcile disparate results across the measures (Table 2) ; however, new combinatorial measures, such as CombiWISE, 41 have the potential to overcome the biases in any particular test. Furthermore, outcome measures may also need to be tailored to best correspond to the disease course in specific sub-populations of progressive patients.
The field is working toward the use of fluid-based biomarkers to monitor progression, which is expected to be more time and cost effective than current methods, and to improve patient stratification. 42 The elevation of certain factors in cerebrospinal fluid (CSF) and/or serum, such as neurofilament light 43 and glial fibrillary acidic protein (GFAP), 44 has been associated Shown are data for patients in the treatment arm (baseline demographic and disease characteristics for patients in the placebo arm were not included).
The features in bold represent patient characteristics most associated with trial outcomes.
with neurodegeneration. However, these factors are typically identified through cross-sectional studies, and no single factor has been found to be a reliable indicator of progression at the individual level. In the meantime, MRI measures of neurodegeneration, such as whole brain atrophy, are increasingly incorporated into progressive trials 45 (Table 2) . But since these methods of measuring brain volume detect very small units of change, they are subject to confounders if not carefully controlled for age, gender, and level of inflammation. Neuroprotective activity could potentially be obscured by anti-inflammation associated "pseudoatrophy," 46 and while cortical thickness is considered more sensitive, 47 this measure can be confounded by its relation to age 48 and intracranial volume. 49 Optical coherence tomography measures of optic nerve thickness are beginning to be used in trials, as they are reliable correlates of brain degeneration in MS 50 and easier to perform and standardize than MRI measures. 51 Ideally, it would be most useful to have measures related to drivers of progression which could be detected early in the disease course and predict future progression. Recent MRI advances have allowed detection of the differential distribution of brain iron in RRMS compared to PMS. 52 Furthermore, the monitoring of iron levels could potentially be a tool for predicting progression, as decreased thalamic iron levels has been associated with faster progression. 53, 54 Trial comparisons As demonstrated by the interferon-beta trials, 6,7 trial design differences, such as patient selection, can affect trial success. 3 Consequently, the different results in trials for similar drugs in the anti-CD20 and S1P modulator families raise the concern whether this stems from differences in biological activity or trial design.
Anti-CD20 therapy: rituximab and ocrelizumab
Anti-CD20 therapy primarily targets B cells and is very effective for reducing relapse rate in RRMS. 55 The depletion of B cells is thought to impact the activation status and function of the remaining T cells. 56, 57 The chimeric anti-CD20 monoclonal antibody rituximab failed to decrease 3-month confirmed disability progression (CDP) assessed by a change in EDSS in the PPMS OLYMPUS trial, but post hoc analysis revealed that there was a small benefit to a sub-population of active early-stage PPMS patients who were younger and had more Gd+-enhancing lesions. 9 Ocrelizumab, a second-generation humanized anti-CD20 therapy, was engineered to be slightly more effective at activating cell death in CD20 expressing cells. While the patient cohorts in the two trials were comparable in terms of EDSS and Gd+-enhancing lesions, the ORATORIO trial for ocrelizumab had a higher percentage of the younger PPMS patients with shorter disease duration. 10 Ocrelizumab was found to decrease 3-and 6-month CDP, slow the performance decline in the T25FW, and decrease brain volume loss (BVL) compared to placebo, 10 which led to its recent approval for PPMS. However, based on the OLYMPUS trial, it appears that rituximab may have similar efficacy for active earlystage PPMS, and it remains unclear if anti-CD20 therapy actually slows progression for older-and late-stage PPMS patients, or if its efficacy is more limited to a particular sub-population which was overrepresented in the ORATORIO trial.
S1P modulators: fingolimod and siponimod
The functional antagonism of S1PR1 reduces the level of circulating pro-inflammatory lymphocytes, 58 which is believed to contribute to the efficacy for S1P modulators in RRMS. 59 Fingolimod was shown to decrease BVL in RRMS 60, 61 and in vitro studies indicated neuroprotective potential, 62, 63 suggesting it may also benefit PMS. The INFORMS trial tested the efficacy of fingolimod in PPMS, but failed to meet its primary endpoint of a change in 3-month CDP compared to baseline or lead to a reduction in BVL. 12 Notably, this trial used composite assessment of disability progression by also incorporating the T25FW and the 9-HPT. Similar to ocrelizumab, fingolimod treatment reduced Gd+-enhancing lesions, but the percentage of patients (14%) with these inflammatory lesions at baseline was half of that in the ORATORIO trial 10, 12 and did not translate into a corresponding reduction in the rate of disease progression.
In contrast, siponimod was recently shown to have clinical efficacy for SPMS in slowing 3-month CDP based only on EDSS, decreasing T1 Gd+-enhancing lesions, and decreasing BVL relative to baseline in the EXPAND trial. 13 Although modest, the success of this trial is notable due to the high percentage of patients (64%) well into the progressive phase of the disease, defined as not experiencing a relapse for at least 2 years prior to the study. 13 The patients in EXPAND were older and had longer disease duration and higher EDSS scores than in other positive trials 13 (Table 1) , suggesting efficacy for non-inflammatory-associated progression.
The INFORMS and EXPAND trials included patients with different forms of PMS, which may have different etiologies, thus the results may not be directly translatable. 64 The differential S1P receptor specificity for these two therapeutic agents may also play a role. Fingolimod acts on S1P receptors 1, 3, 4, and 5, while siponimod is more narrowly targeted to S1P receptors 1 and 5. 59 S1PR1 selective agents have shown benefits in animal models of neurodegeneration, 65, 66 and S1PR5 is expressed by oligodendrocytes, 67 suggesting that these are the dominant receptors responsible for mediating CNS effects. However, human astrocytes can mediate S1P signaling through either S1PR1 or S1PR3, 68 thus the difference in selectivity for S1PR3 may underlie the differential activity in PMS. Ultimately, further studies are needed to tease out whether the efficacy of siponimod in SPMS is dependent on intrinsic neuroprotective activity.
Moving forward
In order to find DMTs effective for inactive PMS, the focus has shifted to neuroprotective agents with neurodegeneration-focused outcome measures. 45 There have been a few recent promising Phase 2 trials (Table 3) , however, as demonstrated by the recent failure of laquinimod 69 to slow MS disease progression; 70 these results based on imaging outcomes may not hold up when using more comprehensive clinical outcomes in Phase 3 trials.
Ibudilast is a phosphodiesterase inhibitor (4, 10), macrophage migration inhibitory factor (MIF) inhibitor, and TLR4 functional antagonist used as an anti-asthmatic treatment in Japan. 71 Ibudilast can readily cross the blood-brain barrier (BBB) and has been shown to protect against microglial-induced neurotoxicity through the inhibition of inflammation and induction of neurotrophic factors. 72 It had no effect on relapse rate or inflammatory lesion load in RRMS, calling into question its therapeutic mechanism of action, yet it did slow BVLs, suggesting it may benefit progressive patients. 73 The completed SPRINT-MS trial in PPMS and SPMS found a significant reduction in their primary endpoint of brain atrophy at 96 weeks comparing ibudilast to placebo, 38 which paves the way for its use in a larger Phase 3 trial.
Biotin has come to be sought after by MS patients following the positive results of two small studies examining the effect of high-dose pharmaceutical-grade oral biotin (300 mg) on disability progression in PMS. 36, 74 Shown are data for patients in the treatment arm (baseline demographic and disease characteristics for patients in the placebo arm were not included). "-" indicates data were not reported for this study.
As an essential coenzyme involved in brain energy metabolism and myelin synthesis, biotin's protective effect is thought to stem from enhanced remyelination. 75 The MS-SPI trial used disability improvement as measured by a change EDSS or the T25FW and found that approximately 13% of progressive patients treated with biotin experienced disability improvement. 36 However, a more recent study with 43 progressive patients found that none of the patients improved and EDSS measured disability actually worsened in onethird of biotin-treated patients. 76 Another report found that high-dose biotin exacerbated inflammatory activity in a subset of MS patients. 77 It has also been suggested that the levels of other essential nutrients, such as iron, could impact the efficacy of biotin supplementation. 78 An ongoing Phase 3 trial (NCT02936037) is expected to settle these conflicting results.
Lipoic acid is an antioxidant suggested to have neuroprotective properties. 79 It is involved in the reduction of Fe 3+ to Fe 2+ and may help prevent iron overload associated toxicity. 80 Treatment with lipoic acid decreased brain atrophy as measured by the percent change in brain volume in SPMS patients. 39 However, all other CNS imaging associated and clinical measures failed to show significant benefits, but may stem from lack of power due to the small sample size. 39 A larger follow-up cohort is needed to adequately interpret the results of this study.
Simvastatin is used to prevent atherosclerosis-related complications and was tested in MS based on its immunomodulatory and neuroprotective activity. 81 Although best known for their effects on triglycerides, statins also reduce ferritin levels and deplete iron stores. 82, 83 Although not effective for RRMS, 84 it was found to reduce the percent change in BVL as well as reduce the rate of change in EDSS and MSFC scores in patients with SPMS. 40 In addition, a sub-study of this trial revealed cognitive and quality of life improvements with simvastatin treatment. 85 The clinical efficacy of simvastatin in SPMS will be determined in an upcoming Phase 3 trial (NCT03387670).
Conclusion
The greatest impediment to developing effective treatments for PMS continues to be the lack of clear biological mechanisms underlying disease progression. However, the recent success of ocrelizumab and siponimod for at least some subsets of PMS patients provides the unprecedented opportunity to try to tease apart these mechanisms through comparisons of clinical responders and non-responders. These studies could also facilitate the development of new biomarkers directly related to the physiology of progression. Since iron regulation is a proposed activity of several of the prospective PMS DMTs, the monitoring of iron levels may be useful to determine patients most likely to benefit and measure efficacy. However, due to the multifaceted nature of progression, combinatorial metrics are likely going to be needed. The mixed results of past trials highlight the need for better patient stratification and correspondingly tailored outcome measures. Due to the heterogeneous nature of the PMS patient population, there needs to be a shift from a "one size fits all" to a more targeted approach.
